drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified chimeric antigen receptor T-cell therapy; patient T cells engineered ex vivo to express a CAR targeting Nectin-4 (PVRL4) on tumor cells, enabling MHC-independent recognition, T-cell activation, cytokine release, and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered ex vivo to express a chimeric antigen receptor that recognizes Nectin-4 (PVRL4) on tumor cells. CAR engagement triggers CD3ζ/co-stimulatory signaling, leading to MHC-independent T-cell activation, cytokine release, expansion, and direct cytotoxic killing of Nectin-4–positive cancer cells.
drug_name
XKDCT293 (Nectin-4 CAR-T)
nct_id_drug_ref
NCT06724835